<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">39343860</PMID><DateRevised><Year>2024</Year><Month>09</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1179-190X</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2024</Year><Month>Sep</Month><Day>30</Day></PubDate></JournalIssue><Title>BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy</Title><ISOAbbreviation>BioDrugs</ISOAbbreviation></Journal><ArticleTitle>Introducing the Biosimilar Paradigm to Neurology: The Totality of Evidence for the First Biosimilar Natalizumab.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1007/s40259-024-00671-4</ELocationID><Abstract><AbstractText>A biosimilar medicine is a successor to a reference ('originator'/'original-brand') biologic medicine brought to market once the patent and exclusive marketing rights for the reference have expired. Biosimilar natalizumab (PB006 [biosim-NTZ]; developed by Polpharma Biologics S.A. and marketed globally as Tyruko<sup>®</sup>; Sandoz) has been developed as a successor to reference natalizumab (Tysabri<sup>®</sup> [ref-NTZ]; Biogen) and is the first US Food and Drug Administration (FDA)-approved and European Medicines Agency (EMA)-approved biosimilar in neurology. As per the FDA and EMA indications for ref-NTZ, biosim-NTZ is approved to treat relapsing forms of multiple sclerosis (USA, EU) and Crohn's disease (USA only). Approval of biosim-NTZ was based on the 'totality of evidence', a comprehensive body of data collected during the development process, demonstrating similarity to its reference medicine. The foundational step of demonstrating structural and functional similarity between biosim-NTZ and ref-NTZ confirmed identical primary and indistinguishable higher order structures, as well as matching binding affinity to α4β1/α4β7 integrins. Following the confirmation of matching structure and function, pharmacokinetic/pharmacodynamic similarity of biosim-NTZ to ref-NTZ in healthy subjects was demonstrated, with no clinically meaningful differences identified in safety and immunogenicity. A comparative, double-blind, randomized study (Antelope) was also conducted in patients with relapsing-remitting multiple sclerosis and demonstrated matching efficacy, safety, and immunogenicity with no clinically meaningful differences between biosim-NTZ and ref-NTZ. This review presents the totality of evidence that confirmed the biosimilarity of biosimilar natalizumab to its reference medicine, which supported its approval by the FDA and the EMA. [Graphical plain language summary available].</AbstractText><CopyrightInformation>© 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Selmaj</LastName><ForeName>Krzysztof</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Neurology, Center of Neurology, University of Warmia &amp; Mazury, Olsztyn, Lodz, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Roth</LastName><ForeName>Karsten</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Polpharma Biologics S.A., Gdansk, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Höfler</LastName><ForeName>Josef</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Staburo GmbH, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vitzithum</LastName><ForeName>Klaus</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Polpharma Biologics S.A., Gdansk, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Derlacz</LastName><ForeName>Rafał</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Polpharma Biologics S.A., Gdansk, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>von Richter</LastName><ForeName>Oliver</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Hexal AG (a Sandoz company), Holzkirchen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hornuss</LastName><ForeName>Cyrill</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Hexal AG (a Sandoz company), Holzkirchen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Poetzl</LastName><ForeName>Johann</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Hexal AG (a Sandoz company), Holzkirchen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Singer</LastName><ForeName>Barry</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>The MS Center for Innovations in Care, Missouri Baptist Medical Center, St Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jacobs</LastName><ForeName>Laura</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Hexal AG (a Sandoz company), Holzkirchen, Germany. laura.jacobs@sandoz.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>New Zealand</Country><MedlineTA>BioDrugs</MedlineTA><NlmUniqueID>9705305</NlmUniqueID><ISSNLinking>1173-8804</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>7</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>30</Day><Hour>0</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>30</Day><Hour>0</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>29</Day><Hour>23</Hour><Minute>11</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39343860</ArticleId><ArticleId IdType="doi">10.1007/s40259-024-00671-4</ArticleId><ArticleId IdType="pii">10.1007/s40259-024-00671-4</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ghasemi N, Razavi S, Nikzad E. Multiple sclerosis: pathogenesis, symptoms, diagnoses and cell-based therapy. Cell J. 2017;19:1–10.</Citation><ArticleIdList><ArticleId IdType="pubmed">28367411</ArticleId></ArticleIdList></Reference><Reference><Citation>McGinley MP, Goldschmidt CH, Rae-Grant AD. Diagnosis and treatment of multiple sclerosis: a review. JAMA. 2021;325:765–79.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.26858</ArticleId><ArticleId IdType="pubmed">33620411</ArticleId></ArticleIdList></Reference><Reference><Citation>Cunill V, Massot M, Clemente A, et al. Relapsing-remitting multiple sclerosis is characterized by a T follicular cell pro-inflammatory shift, reverted by dimethyl fumarate treatment. Front Immunol. 2018;9:1097.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2018.01097</ArticleId><ArticleId IdType="pubmed">29896193</ArticleId><ArticleId IdType="pmc">5986897</ArticleId></ArticleIdList></Reference><Reference><Citation>Brownlee WJ, Wolf C, Hartung HP, et al. Use of follow-on disease-modifying treatments for multiple sclerosis: consensus recommendations. Mult Scler. 2022;28:2177–89.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/13524585221116269</ArticleId><ArticleId IdType="pubmed">36000489</ArticleId></ArticleIdList></Reference><Reference><Citation>Voge NV, Alvarez E. Monoclonal antibodies in multiple sclerosis: present and future. Biomedicines. 2019;7:20.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biomedicines7010020</ArticleId><ArticleId IdType="pubmed">30875812</ArticleId><ArticleId IdType="pmc">6466331</ArticleId></ArticleIdList></Reference><Reference><Citation>McCamish M, Yoon W, McKay J. Biosimilars: biologics that meet patients’ needs and healthcare economics. Am J Manag Care. 2016;22:S439–42.</Citation><ArticleIdList><ArticleId IdType="pubmed">28719221</ArticleId></ArticleIdList></Reference><Reference><Citation>EMA. Biosimilars in the EU: information guide for healthcare professionals. 2019. Available from: https://www.ema.europa.eu/en/documents/leaflet/biosimilars-eu-information-guide-healthcare-professionals_en.pdf . Accessed 3 Mar 2023.</Citation></Reference><Reference><Citation>US FDA. Biosimilar and interchangeable biologics: more treatment choices. 2023. Available from: https://www.fda.gov/consumers/consumer-updates/biosimilar-and-interchangeable-biologics-more-treatment-choices . Accessed 3 Oct 2023.</Citation></Reference><Reference><Citation>US FDA. Biosimilar development process. 2023. Available from: https://www.fda.gov/files/drugs/published/Biosimilar-Development-Process.pdf . Accessed 2 Oct 2023.</Citation></Reference><Reference><Citation>Herndon TM, Ausin C, Brahme NN, et al. Safety outcomes when switching between biosimilars and reference biologics: a systematic review and meta-analysis. PLoS ONE. 2023;18: e0292231.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0292231</ArticleId><ArticleId IdType="pubmed">37788264</ArticleId><ArticleId IdType="pmc">10547155</ArticleId></ArticleIdList></Reference><Reference><Citation>Mysler E, Azevedo VF, Danese S, et al. Biosimilar-to-biosimilar switching: what is the rationale and current experience? Drugs. 2021;81:1859–79.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40265-021-01610-1</ArticleId><ArticleId IdType="pubmed">34705255</ArticleId><ArticleId IdType="pmc">8578069</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen HP, Hachaichi S, Bodenmueller W, Kvien TK, Danese S, Blauvelt A. Switching from one biosimilar to another biosimilar of the same reference biologic: a systematic review of studies. BioDrugs. 2022;36:625–37.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40259-022-00546-6</ArticleId><ArticleId IdType="pubmed">35881304</ArticleId><ArticleId IdType="pmc">9485085</ArticleId></ArticleIdList></Reference><Reference><Citation>Allocati E, Godman B, Gobbi M, Garattini S, Banzi R. Switching among biosimilars: a review of clinical evidence. Front Pharmacol. 2022;13:1–10.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2022.917814</ArticleId></ArticleIdList></Reference><Reference><Citation>Gascón P, Tesch H, Verpoort K, et al. Clinical experience with Zarzio<sup>®</sup> in Europe: what have we learned? Support Care Cancer. 2013;21:2925–32.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00520-013-1911-7</ArticleId><ArticleId IdType="pubmed">23903799</ArticleId><ArticleId IdType="pmc">3765845</ArticleId></ArticleIdList></Reference><Reference><Citation>Greenberg B, Giovannoni G. A place for biosimilars in the changing multiple sclerosis treatment landscape. Mult Scler Relat Disord. 2023;77:1–13.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.msard.2023.104841</ArticleId></ArticleIdList></Reference><Reference><Citation>Müskens WD, Van Dartel SAAR, Riel PLCMV, Adang EMM. Does etanercept biosimilar prescription in a rheumatology center bend the medication cost curve? J Rheumatol. 2021;48:1803–9.</Citation><ArticleIdList><ArticleId IdType="doi">10.3899/jrheum.200565</ArticleId><ArticleId IdType="pubmed">33132223</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhat S, Altajar S, Shankar D, et al. Process and clinical outcomes of a biosimilar adoption program with infliximab-Dyyb. J Manag Care Spec Pharm. 2020;26:410–6.</Citation><ArticleIdList><ArticleId IdType="pubmed">32223602</ArticleId></ArticleIdList></Reference><Reference><Citation>Tinsley SM, Grande C, Olson K, Plato L, Jacobs I. Potential of biosimilars to increase access to biologics: considerations for advanced practice providers in oncology. J Adv Pract Oncol. 2018;9:699–716.</Citation><ArticleIdList><ArticleId IdType="pubmed">31249718</ArticleId><ArticleId IdType="pmc">6570521</ArticleId></ArticleIdList></Reference><Reference><Citation>Rivera VM. Biosimilar drugs for multiple sclerosis: an unmet international need or a regulatory risk? Neurol Ther. 2019;8:177–84.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40120-019-0145-0</ArticleId><ArticleId IdType="pubmed">31313222</ArticleId><ArticleId IdType="pmc">6858917</ArticleId></ArticleIdList></Reference><Reference><Citation>IMS. Delivering on the potential of biosimilar medicines. 2016. Available from: https://www.medicinesforeurope.com/wp-content/uploads/2016/03/IMS-Institute-Biosimilar-Report-March-2016-FINAL.pdf . Accessed 3 Mar 2023.</Citation></Reference><Reference><Citation>Markus R, Liu J, Ramchandani M, Landa D, Born T, Kaur P. Developing the totality of evidence for biosimilars: regulatory considerations and building confidence for the healthcare community. BioDrugs. 2017;31:175–87.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40259-017-0218-5</ArticleId><ArticleId IdType="pubmed">28439817</ArticleId><ArticleId IdType="pmc">5443883</ArticleId></ArticleIdList></Reference><Reference><Citation>US FDA. Scientific considerations in demonstrating biosimilarity to a reference product. 2015. Available from: https://www.fda.gov/media/82647/download . Accessed 3 Mar 2023.</Citation></Reference><Reference><Citation>Holzmann J, Balser S, Windisch J. Totality of the evidence at work: the first U.S. biosimilar. Expert Opin Biol Ther. 2016;16:137–42.</Citation><ArticleIdList><ArticleId IdType="doi">10.1517/14712598.2016.1128410</ArticleId><ArticleId IdType="pubmed">26634611</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO. Guidelines on evaluation of biosimilars. 2022. Available from: https://cdn.who.int/media/docs/default-source/biologicals/annex-3---who-guidelines-on-evaluation-of-biosimilars---sj-ik-5-may-2022.pdf?sfvrsn=9b2fa6d2_1&amp;download=true . Accessed 10 May 2024.</Citation></Reference><Reference><Citation>EMA. Concept paper for the development of a reflection paper on a tailored clinical approach in biosimilar development. November 24, 2023. Available from: https://www.ema.europa.eu/en/documents/other/concept-paper-development-reflection-paper-tailored-clinical-approach-biosimilar-development_en.pdf . Accessed 10 May 2024.</Citation></Reference><Reference><Citation>Kurki P, Kang HN, Ekman N, Knezevic I, Weise M, Wolff-Holz E. Regulatory evaluation of biosimilars: refinement of principles based on the scientific evidence and clinical experience. BioDrugs. 2022;36:359–71.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40259-022-00533-x</ArticleId><ArticleId IdType="pubmed">35596890</ArticleId><ArticleId IdType="pmc">9148871</ArticleId></ArticleIdList></Reference><Reference><Citation>Sandoz GmbH. Tyruko<sup>®</sup> (natalizumab): summary of product characteristics. 2023. Available from: https://www.ema.europa.eu/documents/product-information/tyruko-epar-product-information_en.pdf . Accessed 2 Oct 2023.</Citation></Reference><Reference><Citation>US FDA. FDA approves first biosimilar to treat multiple sclerosis. 2023. Available from: https://www.fda.gov/news-events/press-announcements/fda-approves-first-biosimilar-treat-multiple-sclerosis . Accessed 30 Aug 2023.</Citation></Reference><Reference><Citation>Biogen Netherlands B.V. Tysabri<sup>®</sup> (natalizumab): summary of product characteristics. 2022. Available from: https://www.ema.europa.eu/documents/product-information/tysabri-epar-product-information_en.pdf . Accessed 6 Apr 2023.</Citation></Reference><Reference><Citation>Biogen Inc. Tysabri<sup>®</sup> (natalizumab): prescribing information. December 2023. Available from: https://www.tysabri.com/content/dam/commercial/tysabri/pat/en_us/pdf/tysabri_prescribing_information.pdf . Accessed 2 Oct 2023.</Citation></Reference><Reference><Citation>Sandoz Inc. Tyruko<sup>®</sup> (natalizumab-sztn): prescribing information. 2023. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761322s000lbl.pdf . Accessed 27 Oct 2023.</Citation></Reference><Reference><Citation>Rudick RA, Sandrock A. Natalizumab: α4-integrin antagonist selective adhesion molecule inhibitors for MS. Expert Rev Neurother. 2004;4:571–80.</Citation><ArticleIdList><ArticleId IdType="doi">10.1586/14737175.4.4.571</ArticleId><ArticleId IdType="pubmed">15853576</ArticleId></ArticleIdList></Reference><Reference><Citation>Morrow SA, Clift F, Devonshire V, et al. Use of natalizumab in persons with multiple sclerosis: 2022 update. Mult Scler Relat Disord. 2022;65: 103995.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.msard.2022.103995</ArticleId><ArticleId IdType="pubmed">35810718</ArticleId></ArticleIdList></Reference><Reference><Citation>Guagnozzi D, Caprilli R. Natalizumab in the treatment of Crohn’s disease. Biologics. 2008;2:275–84.</Citation><ArticleIdList><ArticleId IdType="pubmed">19707360</ArticleId><ArticleId IdType="pmc">2721358</ArticleId></ArticleIdList></Reference><Reference><Citation>US FDA. Tyruko product quality review. 2023. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/761322Orig1s000ChemR.pdf . Accessed 9 May 2024.</Citation></Reference><Reference><Citation>EMA. Tyruko assessment report. July 20, 2023. Available from: https://www.ema.europa.eu/en/documents/assessment-report/tyruko-epar-public-assessment-report_en.pdf . Accessed 9 May 2024.</Citation></Reference><Reference><Citation>GaBI. EC approval of natalizumab, aflibercept and tocilizumab biosimilars. November 2023. Available from: https://gabionline.net/biosimilars/news/ec-approval-of-natalizumab-aflibercept-andtocilizumab-biosimilars . Accessed 31 Jan 2024.</Citation></Reference><Reference><Citation>EMA. Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues. 2014. Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-similar-biological-medicinal-products-containing-biotechnology-derived-proteins-active_en-2.pdf . Accessed 3 Mar 2023.</Citation></Reference><Reference><Citation>Vulto AG, Jaquez OA. The process defines the product: what really matters in biosimilar design and production? Rheumatology. 2017;56:iv14-29.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/kex278</ArticleId><ArticleId IdType="pubmed">28903544</ArticleId><ArticleId IdType="pmc">5850795</ArticleId></ArticleIdList></Reference><Reference><Citation>Mascarenhas-Melo F, Diaz M, Gonçalves MBS, et al. An overview of biosimilars: development, quality, regulatory issues, and management in healthcare. Pharmaceuticals. 2024;17:1–25.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ph17020235</ArticleId></ArticleIdList></Reference><Reference><Citation>Guillen E, Ekman N, Barry S, Weise M, Wolff-Holz E. A data driven approach to support tailored clinical programs for biosimilar monoclonal antibodies. Clin Pharmacol Ther. 2023;113:108–23.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cpt.2785</ArticleId><ArticleId IdType="pubmed">36546547</ArticleId></ArticleIdList></Reference><Reference><Citation>Markus R, McBride HJ, Ramchandani M, et al. A review of the totality of evidence supporting the development of the first adalimumab biosimilar ABP 501. Adv Ther. 2019;36:1833–50.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12325-019-00979-6</ArticleId><ArticleId IdType="pubmed">31183781</ArticleId><ArticleId IdType="pmc">6822859</ArticleId></ArticleIdList></Reference><Reference><Citation>Vandekerckhove K, Seidl A, Gutka H, et al. Rational selection, criticality assessment, and tiering of quality attributes and test methods for analytical similarity evaluation of biosimilars. AAPS J. 2018;20:1–9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1208/s12248-018-0230-9</ArticleId></ArticleIdList></Reference><Reference><Citation>Selmaj K, Roth K, Höfler J, et al. The totality of evidence for proposed biosimilar natalizumab PB006 confirms biosimilarity to its reference medicine. In: Poster DMT62. Consortium of Multiple Sclerosis Centers; 2023. Accessed 3 may 2023.</Citation></Reference><Reference><Citation>EMA. ICH guideline Q9 on quality risk management. September 2015. Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/international-conference-harmonisation-technical-requirements-registration-pharmaceuticals-human-use-ich-guideline-q9-quality-risk-management-step-5-first-version_en.pdf . Accessed 14 May 2024.</Citation></Reference><Reference><Citation>Labrijn AF, Buijsse AO, van den Bremer ETJ, et al. Therapeutic IgG4 antibodies engage in Fab-arm exchange with endogenous human IgG4 in vivo. Nat Biotechnol. 2009;27:767–71.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nbt.1553</ArticleId><ArticleId IdType="pubmed">19620983</ArticleId></ArticleIdList></Reference><Reference><Citation>Vidarsson G, Dekkers G, Rispens T. IgG subclasses and allotypes: from structure to effector functions. Front Immunol. 2014;5:520.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2014.00520</ArticleId><ArticleId IdType="pubmed">25368619</ArticleId><ArticleId IdType="pmc">4202688</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Neut KM, Schuurman J, Losen M, et al. Anti-inflammatory activity of human IgG4 antibodies by dynamic Fab arm exchange. Science. 1979;2007(317):1554–7.</Citation></Reference><Reference><Citation>Wessels H, von Richter O, Velinova M, et al. Pharmacokinetic and pharmacodynamic similarity of biosimilar natalizumab (PB006) to its reference medicine: a randomized controlled trial. Expert Opin Biol Ther. 2023;23:1287–97.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14712598.2023.2290530</ArticleId><ArticleId IdType="pubmed">38044885</ArticleId></ArticleIdList></Reference><Reference><Citation>Hemmer B, Wiendl H, Roth K, et al. Efficacy and safety of proposed biosimilar natalizumab (PB006) in patients with relapsing-remitting multiple sclerosis: the Antelope phase 3 randomized clinical trial. JAMA Neurol. 2023;80:298–307.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2022.5007</ArticleId><ArticleId IdType="pubmed">36689214</ArticleId><ArticleId IdType="pmc">9871944</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller DH, Khan OA, Sheremata WA, et al. A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2003;348:15–23.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa020696</ArticleId><ArticleId IdType="pubmed">12510038</ArticleId></ArticleIdList></Reference><Reference><Citation>Akaishi T, Misu T, Fujihara K, et al. White blood cell count profiles in multiple sclerosis during attacks before the initiation of acute and chronic treatments. Sci Rep. 2021;11:1–9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-021-01942-8</ArticleId></ArticleIdList></Reference><Reference><Citation>Vennegoor A, Rispens T, Strijbis EM, et al. Clinical relevance of serum natalizumab concentration and anti-natalizumab antibodies in multiple sclerosis. Mult Scler. 2013;19:593–600.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1352458512460604</ArticleId><ArticleId IdType="pubmed">22992450</ArticleId></ArticleIdList></Reference><Reference><Citation>Calabresi PA, Giovannoni G, Confavreux C, et al. The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL. Neurology. 2007;69:1391–403.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.wnl.0000277457.17420.b5</ArticleId><ArticleId IdType="pubmed">17761550</ArticleId></ArticleIdList></Reference><Reference><Citation>Subramanyam M. Case study: immunogenicity of natalizumab. In: . Immunogenicity of biopharmaceuticals. Ed: Weert Mv and Møller EH. New York (NY): Springer; 2008, p. 173–87.</Citation></Reference><Reference><Citation>Ciano-Petersen NL, Aliaga-Gaspar P, Hurtado-Guerrero I, et al. Natalizumab-immunogenicity evaluation in patients with infusion related events or disease exacerbations. Front Immunol. 2023;14:1242508.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2023.1242508</ArticleId><ArticleId IdType="pubmed">37675113</ArticleId><ArticleId IdType="pmc">10478078</ArticleId></ArticleIdList></Reference><Reference><Citation>Polman CH, O’Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2006;354:899–910.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa044397</ArticleId><ArticleId IdType="pubmed">16510744</ArticleId></ArticleIdList></Reference><Reference><Citation>CHMP. Tysabri assessment report. 2021. Available from: https://www.ema.europa.eu/en/documents/variation-report/tysabri-h-c-603-x-0116-epar-assessment-report-extension_en.pdf . Accessed 3 Oct 2023.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle>